Barclays PLC Sells 157,105 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Barclays PLC decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 32.5% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 325,921 shares of the biopharmaceutical company’s stock after selling 157,105 shares during the period. Barclays PLC’s holdings in Regeneron Pharmaceuticals were worth $183,256,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Salomon & Ludwin LLC acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at about $31,000. Caitlin John LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at about $34,000. Traub Capital Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $38,000. Finally, Berbice Capital Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 300.0% during the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 60 shares during the period. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. The trade was a 32.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 5,274 shares of company stock worth $4,142,738 over the last 90 days. Company insiders own 7.02% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research analyst reports. Royal Bank Of Canada upped their target price on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a research note on Monday, March 2nd. Evercore boosted their price target on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a report on Thursday, January 22nd. HSBC raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Finally, Guggenheim boosted their target price on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $802.27.

Regeneron Pharmaceuticals Trading Down 0.7%

Shares of NASDAQ:REGN opened at $759.82 on Friday. The company’s 50-day moving average price is $770.81 and its two-hundred day moving average price is $687.94. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The stock has a market capitalization of $80.33 billion, a PE ratio of 18.28, a price-to-earnings-growth ratio of 2.06 and a beta of 0.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating the consensus estimate of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter last year, the company earned $12.07 EPS. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a $0.94 dividend. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 9.05%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.